Skip to content
Menu

Zeev Bovan

688 posts

Posts (688)

Zeev Bovan PLTR 9 months ago #634

GP where this is going? Where is the bottom here?

Zeev Bovan NVDA 9 months ago #636

It will never get old because fools don’t die, they multiply. It was never a zero sum game, some have to lose for others to gain. I will buy again after the sharks are done eating.

Zeev Bovan NVDA 9 months ago #637

I have seen this before, pump in a parabolical way, dumped shortly after.

Zeev Bovan TARA 9 months ago #639

Upcoming Catalyst Timeline (2026)
? Feb 26–28, 2026 — ASCO Genitourinary Symposium
Protara will present updated interim data from the Phase 2 ADVANCED-2 trial in bladder cancer (BCG-unresponsive cohort) at the ASCO Genitourinary Cancers Symposium in San Francisco.
Data results here — especially on response rates and safety — are a major short-term catalyst because they’ll be one of the first fresh readouts on the registrational cohort.
? Q1 2026 — Interim ADVANCED-2 Readout
Protara expects to announce interim results for ~25 six-month evaluable patients from the BCG-unresponsive arm of the ADVANCED-2 trial in Q1 2026.
This is a key near-term trading catalyst — positive stats here could drive sentiment sharply higher; weak or muddled data could have the opposite effect.
? 2026 (H1) — FDA/Registrational Updates
The company expects to provide regulatory path updates and potentially outline the design of registrational trials (e.g., pivotal comparisons vs. standard chemo).
Official FDA feedback or new regulatory milestones (e.g., End-of-Phase discussions) can be very impactful when they occur.
⚖️ Second Half of 2026 — Registrational and THRIVE-3 Activity
Enrollment completion for the ADVANCED-2 BCG-unresponsive cohort is expected in the second half of 2026.
The THRIVE-3 Phase 3 IV Choline Chloride trial (for patients on long-term parenteral nutrition) may report interim data in H2 2026 — another potential catalyst.
? Other Potential Catalysts
Regulatory decisions on Breakthrough/Fast Track pathways — while not scheduled, updates here can support valuation.
Conference calls/webcasts tied to data reveals typically coincide with these updates and often include management tone and detail beyond press releases.
? Recent Catalyst Recap
These already happened but had market impact:
Dec 2025: Updated interim NMIBC data + regulatory feedback from FDA — presented at SUO meeting, which moved sentiment.
Nov 2025: Positive STARBORN-1 interim results in lymphatic malformations.
Last few months: FDA Breakthrough & Fast Track designations for pediatric LMs.
? Which One Matters Most Next
The biggest potential short-term swing event is:
? Updated Phase 2 ADVANCED-2 data at ASCO (Feb 26–28, 2026)
This is the first major clinical data event of the year.
If the six-month BCG-unresponsive cohort shows strong responses with good safety, that can materially lift sentiment because it’s a registrational pathway signal.
Followed by: the broader Q1 2026 interim readout for that cohort — this may come as an earnings release, webcast, or press announcement in March.

Zeev Bovan BTC.X 9 months ago #640

Crypto was never invented to benefit the retail investors, get out while you still can and invest in real assets like gold and good companies.